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Abstract: Pain is inadequately relieved by escalating doses of a strong opioid analgesic such as
morphine in up to 25% of patients with cancer-related severe pain complicated by a neuropathic
(nerve damage) component. Hence, there is an unmet medical need for research on novel painkiller
strategies. In the present work, we used supercritical fluid polymer encapsulation to develop
sustained-release poly(lactic-co-glycolic acid) (PLGA) biodegradable microparticles containing the
analgesic adjuvant drug ketamine, for injection by the intrathecal route. Using this approach with a
range of PLGA co-polymers, drug loading was in the range 10–60%, with encapsulation efficiency
(EE) of 60–100%. Particles were mainly in the size range 20–45 µm and were produced in the absence
of organic solvents and surfactants/emulsifiers. Investigation of the ketamine release profiles from
these PLGA-based microparticles in vitro showed that release took place over varying periods in the
range 0.5–4.0 weeks. Of the polymers assessed, the ester end-capped PLGA5050DLG-1.5E gave the
best-controlled release profile with drug loading at 10%.
Keywords: analgesic adjuvant; ketamine; cancer pain; drug delivery; poly(lactic-co-glycolic acid)
(PLGA); sustained release
1. Introduction
Unrelenting severe cancer-related pain, particularly that complicated by a neuropathic (nerve
damage) component, is difficult to alleviate by escalating doses of strong opioid analgesics such as
morphine given alone or in combination with adjuvant analgesic agents by conventional systemic
dosing routes [1]. Although cancer can be a terminal disease, there should be no reason to deny
a patient the opportunity to live productively and free of pain [2]. Therefore, the goals of pain control
should be to optimize the patient’s comfort and function whilst avoiding unnecessary adverse effects
from medications [3].
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The intrathecal (i.t.) dosing route enables logarithmic scale reductions in the analgesic/adjuvant
doses needed to produce adequate pain relief because this route bypasses the systemic metabolism
and delivers the drugs near to the receptors/ion channels that transduce pain relief in the spinal
cord [4,5]. Importantly, there is some evidence that, in the postoperative setting, adding ketamine to
an opioid in patient-controlled analgesia has a beneficial effect on pain relief, is morphine-sparing,
and produces less postoperative nausea and vomiting compared with equi-effective opioid analgesic
administration alone [6,7]. The efficacy of ketamine alone as an analgesic is still under debate, especially
for indications such as chronic pain [8]. When used as an analgesic, sub-anaesthetic doses of ketamine
are administered [9]. In rodents, co-injection of ketamine with a strong opioid analgesic attenuated the
development of analgesic tolerance and enhanced pain relief [10]. Together, these findings suggest
that i.t. co-administration of a strong opioid analgesic with low-dose ketamine in close proximity to
their target receptors/ion channels in the spinal cord may produce satisfactory analgesia.
As implantable i.t. delivery devices are associated with a range of catheter-related problems
in up to 25% of patients [11] and the surgery is highly invasive, it is clear that new therapeutic
approaches are needed. One such strategy is the development of sustained-release biodegradable
microparticles for i.t. injection with the potential to restore satisfactory analgesia in patients who
would otherwise suffer from intractable cancer-related pain despite the administration of escalating
doses of a strong opioid analgesic by conventional oral or parenteral dosing routes [12]. However,
successful microencapsulation of analgesic/adjuvant drugs of interest must overcome the challenges
of poor drug loading, unacceptably high initial burst release, inadequate sustained-release period,
and contamination by unacceptable organic solvent residues.
Polymeric particles are widely used in the field of drug delivery [12–14]. The most
appropriate carriers for sustained drug delivery are slowly degrading polymers. For example,
poly(lactic-co-glycolic) acid (PLGA) and poly(lactic acid) (PLA) are biocompatible, biodegradable
polymers that have been approved by the United States Food and Drug Administration (FDA) and
the European Medicines Agency (EMA) for use in systemic drug delivery systems [13]. Of these,
PLGA-based drug-loaded microparticles, commonly prepared by a water-in-oil-in-water (w/o/w)
double-emulsion method or an oil-in-water (o/w) single-emulsion method, hold promise because
of their biodegradability and successful application in a range of systemically administered drug
formulations [14,15].
With the traditional methods of sustained-release microparticle formulation, large quantities
of potentially toxic organic solvents and/or surfactants/emulsifiers are used, possibly leading to
unacceptable levels of residual impurities that necessitate the use of further purification steps to ensure
their removal [16]. In contrast, supercritical CO2 (scCO2) technology provides a means to prepare
particles that are environmentally benign and produce particles that are free from organic solvent
residues after processing [17]. The method is flexible and allows control of the composition of the
polymer mixtures to control the rates of release of the encapsulated molecules [18]. In particular, this
technology provides a clean and reliable method for the production of particles containing therapeutic
molecules such as ketamine.
The use of scCO2 to create drug-loaded particles is of particular interest [19] because of its
relatively mild conditions (7.4 MPa and 31 ◦C), allowing the processing of thermally sensitive
substances [20,21]. By varying the temperature and pressure, the properties of scCO2 can be changed,
enabling it to act as a solvent, antisolvent, solute, or drying agent [22]. Consequently, different particle
characteristics can be designed by adjusting the scCO2 processing conditions including temperature,
pressure, contact time, diffusion processes, and depressurization conditions [23–25].
The precise method of processing using scCO2 depends upon the respective solubilities of
the polymer carrier and the drug in the solvent (scCO2) [26]. Howdle and his team reported a
method for the production of hGH-loaded polyester particles and demonstrated controlled release
in a simian model [27]. In other work, vaccines for tetanus toxoid (TT) were incorporated into
PLA particles using scCO2 processing [28]. A single injection of the polymer-TT particles into mice
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produced similar antibody titres as multiple injections of a commercial alum-adsorbed TT vaccine [28].
These results demonstrate the potential for the preparation of organic solvent-free particles loaded
with the molecules of interest.
The simple CriticalMix process utilizes scCO2 to encapsulate active pharmaceutical ingredients
(APIs) within a biodegradable polymer matrix for sustained-release applications [26,27,29]. Hence,
the aim of our present study was to microencapsulate ketamine into biodegradable polymers to
produce sustained-release microparticle formulations for potential i.t. co-injection with strong
opioid analgesic-loaded microparticles so as to potentially achieve prolonged periods of satisfactory
pain relief.
2. Materials and Methods
2.1. Materials
Various poly(lactic-co-glycolic acid) (PLGA) biodegradable polymers (50:50), (75:25), including
5050DLG-1.5E (5050-1.5E), RG503, RG504, RG7525S, 9010DLG-4.5E (9010-4.5E), 5050DLG-1A (5050-1A),
5050DLG-2A (5050-2A), 5050DLG-4A (5050-4A), 7525DLG-4A (5050-4A), and poly(lactic-acid)
(PLA)-2.5A and R202S, were purchased from Evonik Health care (Birmingham, Al, USA).
The physicochemical characteristics of these polymers are listed in Table 1. Ketamine HCl powder
(98–99%) was from Sigma-Aldrich (Haverhill, UK). Food-grade CO2 was from BOC (Rotherham, UK).
Table 1. Physicochemical properties of the PLGA and PLA polymers.
Polymer No. Polymer Commercial Name Composition Inherent Viscosity (dL/g) End Group
1 PLGA5050DLG-1.5E PLGA 50:50 ~0.2 Ester
2 RG504 PLGA 50:50 0.45–0.60 Ester
3 RG503 PLGA 50:50 0.32–0.44 Ester
4 RG752S PLGA 75:25 0.8–1.2 Ester
5 PLGA9010DLG-4.5E PLGA 90:10 0.4–0.5 Ester
6 R202S PLA 0.16–0.24 Ester
7 PLA-2.5A PLA 0.2–0.3 Acid
8 PLGA5050DLG-1A PLGA 50:50 0.05–0.15 Acid
9 PLGA5050DLG-2A PLGA 50:50 0.15–0.25 Acid
10 PLGA7525DLG-4A PLGA 75:25 0.35–0.45 Acid
PLA, poly(lactic-acid); PLGA, poly(lactic-co-glycolic acid).
2.2. Methods
2.2.1. Preparation of Ketamine-Loaded Polymeric Microparticles
Firstly, ketamine HCl was converted to the corresponding free base by adjusting the pH to ~10
using 2 M NaOH added dropwise according to our previous work (Han et al., 2015). The CritcalMix
scCO2 process was optimised on the basis of that described previously [29]. For each of the polymer
powders listed in Table 1, a weighed amount was mixed with ketamine in varying ratios (Table 2),
and each mixture was loaded into a pressure vessel, pressurised with CO2 and heated to 40 ◦C at
a pressure of 14 MPa. Once the desired temperature was reached, the mixture of CO2/polymer/drug
inside the vessel was mixed using mechanical stirring. Liquefaction of the polymer by scCO2 enabled
the drug to be mixed into the polymer. Approximately 0.5–1.0 h later heating was stopped, and the
polymer/ketamine/scCO2 mixture was allowed to cool to below 25 ◦C before the CO2 was slowly
vented, depressurised through a disk nozzle with a 0.6 mm orifice (unheated), and the polymer
solidified to entrap ketamine and form microparticles containing ketamine. Cooling took place
over a period of one hour with pressure decreasing from 14 MPa scCO2 to 7.5 MPa (~1000 psi).
The microparticles were collected and ground with a pestle and mortar and then sieved through
a 45 µm sieve. The final products were stored refrigerated at a mean (±SD) temperature of 5(±3) ◦C
and protected from light in a desiccator.
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Table 2. Ketamine-loaded microparticles—formulations and incorporation efficiency.
Formulation (F) Polymer Ratio (%) Theoretical Loading (%) Actual Loading (%) Encapsulation Efficiency (EE %)
F1 PLGA-RG504(20%)
PLA-2.5A
(20%) 60 60 (±0.4) 100
F2 PLGA5050-1.5E (40%) 60 58 (±0.4) 97
F3 PLGA5050-1.5E(25%)
PLGA 7525-4A
(15%) 60 54 (±2.2) 90
F4 PLA-2.5A(25%)
PLGA 7525-4A
(15%) 60 58 (±9.7) 97
F5 PLGA5050-1.5E (70%) 30 26 (±1.6) 87
F6 PLGA5050-1.5E (90%) 10 9 (±0.8) 90
F7 PLGA5050-1.5E (80%) 20 16 (±0.6) 80
F8 PLGA5050-1.5E(50%)
PLGA7525-4A
(20%) 30 30 (±2.6) 100
F9 PLGA5050-1.5E(23.3%)
RG503 (23.3%)
RG752S (23.3%) 30 21 (±0.3) 70
F10 PLGA5050-1A(50%)
PLGA7525-4A
(20%) 30 30 (±1.0) 100
F11 PLGA5050-2A (70%) 30 30 (±1.4) 100
F12 PLGA5050-1A (70%) 30 30 (±0.3) 100
F13 PLGA5050-1A(35%)
PLGA7525-4A
(35%) 30 30 (±0.3) 100
F14 PLGA RG503(35%)
PLGA RG752S
(35%) 30 23 (±1.2) 77
F15 PLGA RG503(20%)
PLGA RG752S
(50%) 30 19 (±1.4) 63
F16 RG752S(40%)
PLGA9010-4.5E
(30%) 30 19 (±1.6) 63
F17 PLGA RG752S(50%)
PLA R202S
(20%) 30 30 (±0.4) 100
F18 RG503 (23%) RG752S (57%) 20 18 (±0.3) 88
F19 PLGA RG752S(50%)
PLA R202S
(20%) 20 20 (±1.4) 100
A, Acid end-capped; E, Ester end-capped.
2.2.2. Determination of Drug Incorporation Efficiency
Accurately weighed amounts (~10 mg; n = 3) of the ketamine-loaded polymeric microparticles
(Table 1) were dissolved in acetonitrile. The ketamine concentrations were quantified using HPLC
(Agilent 1200 series) with UV detection at 280 nm. A gradient HPLC method was used for determining
the drug loading (DL) using a Waters XBridge BEH C18 column: 3.5 µm, 3.0× 150 mm. The calibration
range was 5–800 µg/mL. The mean (±SD) correlation coefficients for ketamine calibration curves were
0.9998 (±0.0001).
Drug incorporation efficiency, expressed as actual drug loading (% w/w), and encapsulation
efficiency (EE % w/w) were calculated using Equations (1) and (2), respectively. The individual values
for three replicate determinations and their mean values are reported.
Drug loading (%) = 100 × mass of drug in microparticles/weight of microparticles (1)
EE (%) = 100 × mass of drug in microparticles/mass of drug in microparticles theoretically (2)
2.2.3. Determination of In Vitro Drug Release
Accurately weighed ~20 mg samples of ketamine-loaded polymeric microparticles (n = 3) were
suspended in 1mL of PBS and transferred to dialysis tubes (SnakeSkin™ Dialysis Tubing, 3.5K
MWCO). Each dialysis tube was sealed, placed into a capped container containing 20mL PBS, and then
placed into an incubator maintained at 37.5 ◦C and shaken horizontally at an oscillating frequency of
120 min−1. Sampling time points were 3 and 24 h, 3, 7, 14, 21, and 28 days. At each time point, a 1 mL
aliquot of buffer was taken for analysis and replaced with fresh buffer. The 1 mL samples (n = 3) were
filtered using a 0.2 µm nylon syringe filter into a vial for HPLC analysis of the ketamine concentrations.
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An isocratic HPLC method was optimised for determining the ketamine release profile using
a C18 column: 3.5 µm, 3.0 × 150 mm. The calibration range was 5–800 µg/mL. The mean (±SD)
correlation coefficients for ketamine calibration curves were R2 > 0.9999.
2.3. Morphology and Particle Size
Morphological evaluation of the sustained-release ketamine-loaded PLGA microparticles was
performed using scanning electron microscopy (Jeol IT300, JEOL Ltd., Tokyo, Japan) to determine shape
and surface morphology. The microparticles were sputter-coated with platinum using an Auto Smart
Coater (JFC-1300, JEOL Ltd., Tokyo, Japan) before examination using scanning electron microscopy.
2.4. Data Analysis
The data are presented as mean ± standard deviation (SD) or standard error of the mean (SEM)
(±SD/SEM). Non-linear regression was used to calculate in vitro drug release using GraphPad
PrismTM v7.03 (GraphPad, San Diego, CA, USA). The one-way and two-way ANOVA followed
by the Bonferroni test were used for comparing the means of burst release for the various formulation
trials herein. The statistical significance criterion was p ≤ 0.05. To investigate the ketamine release
kinetics, in vitro drug release data were fitted to various kinetic models, and regression analysis was
performed for the selected formulations. The data were plotted as cumulative percentage drug release
versus time for the zero-order model, square root of time for the Higuchi model, and log time for the
Korsmeyer–Peppas model [30–32].
3. Results
3.1. Successful Encapsulation of Ketamine
A total of 112 trials with various PLGA co-polymers individually, as PLGA blends, or as PLGA
blended with PLA were conducted. Our focus was upon minimisation of the burst and optimisation
of the release profile over 24 h. Thus, we varied temperature, pressure, contact time, stirring rate of the
scCO2/polymer/drug solution, as well as depressurization conditions including CO2 venting rate
and venting temperature to deliver the optimal formulation. Ketamine as a free base is stable under
supercritical CO2 conditions, as no degradation was observed when processed under CriticalMix
conditions (data not shown). Ketamine loading was controlled in the range of 10–60% (Figure 1 and
Table 2). The recovery of ketamine from the microparticle formulations was in the range 60–100%
(mean of 80%) for all trials. Details of the selected 19 formulations of ketamine-loaded microparticles
produced herein are summarized in Table 2, including the mean (±SD) actual drug loading (n = 3)
and EE.
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Figure 1. ean (±SEM) in vitro ketamine percentage of cumulative release in 24 h for a range of
formulations (n = 3). Reducing the ketamine payload from 60% to 30% and from 30% to 10–20%
reduced the burst effect (****, p < 0.0001). One-way ANOVA followed by the Bonferroni test.
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3.2. In Vitro Release Profiles
For all formulations of the ketamine-loaded microparticles there was a higher initial release phase
when the drug loading was increased (Figure 1), followed by a slower nearly zero-order release lasting
for up to 28 days (Figures 2–4).
Pharmaceutics 2018, 10, x FOR PEER REVIEW  6 of 13 
 
 
Figure 1. Mean (±SEM) in vitro ketamine percentage of cumulative release in 24 h for a range of 
formulations (n = 3). Reducing the ketamine payload from 60% to 30% and from 30% to 10–20% 
reduced the burst effect (****, P < 0.0001). One-way ANOVA followed by the Bonferroni test. 
3.2. In Vitro R lease Profiles  
For all formulations of the ketamine-loaded mic oparticl s there was a higher initial release 
phase when the dru  lo di g was increased (Figure 1), followed by a slower nearly zero-ord r release 
lasting for up to 28 day  (Figures 2–4).  
 
Figure 2. Comparison of mean (±SEM) in vitro ketamine release profiles between microparticle 
formulations (n = 3) with ketamine loading at 60% and 30%, 20% and 10%. The 24 h burst release 
decreased significantly (****, P < 0.0001) from 74.6% (● F2, 60% ketamine and 40% PLGA5050-1.5E) to 
27.7% (■ F5, 30% ketamine and 70% PLGA5050-1.5E). Reducing the ketamine load from 30% to 20% 
and 10% using the same polymer, PLGA5050-1.5E, enabled the polymer matrix to have better control 
over ketamine release. Sustained release continued for 14 days when ketamine loading was 30% (■ 
F5), whereas it lasted more than 21 days at 10% ketamine loading (▼ F6). The 24 h burst release was 
reduced significantly from 27.7% to 9.0% (*, P < 0.05) for microparticles at 10% ketamine loading when 
compared with 30% ketamine loading. Ketamine loading at 20% (▲) and 30% (■) did not differ 
significantly (P > 0.05) in terms of release duration, but burst release was reduced from 27.7% to 17.5%. 
Two-way ANOVA followed by the Bonferroni test. F, Formulation. 
Figure 2. Comparison of mean (±SE ) in vitro ketamine release profiles between microparticle
formulations (n = 3) with ketamine loading at 60% and 30%, 20% and 10%. The 24 h burst release
decreased significantly (****, p < 0.0001) fro 74.6 ( F2, 60 keta ine and 40% PLGA5050-1.5E)
to 27.7% ( F5, 30% ketamine and 70% PLGA5050-1.5E). Reducing the ketamine load from 30% to
20% and 10% using the same polymer, PLGA5050-1.5E, enabled the polymer matrix to have better
control over ketamine release. Sustained release continued for 14 days when ketamine loading was
30% ( F5), whereas it lasted more than 21 days at 10% ketamine loading (H F6). The 24 h burst release
was reduced significantly from 27.7% to 9.0% (*, p < 0.05) for microparticles at 10% ketamine loading
when compared with 30% ketamine loading. Ketamine loading at 20% (N) and 30% () did not differ
significantly (p > 0.05) in terms of release duration, but burst release was reduced from 27.7% to 17.5%.
Two-way ANOVA followed by the Bonferroni test. F, Formulation.Pharmaceutics 2018, 10, x FOR PEER REVIEW  7 of 13 
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the three acid end-capped polymers assessed (n = 3). A maximum of one-week sustained release was
achieved in vitro. The cumulative release in 24 h was ~55%, >80% in three days, and 100% in one
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(20%); F11, PLGA5050-2A (70%); F12, PLGA5050-1A (70%).
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reduced the rate of release significantly (*, p < . ; , p . ) hen compared with a blend
of acid end-ca ped PLGAs ( , f - an 20 of PLGA7525-4A). The 24 h burst
rel ase decreased from 53.2% for F10 to 4 . % for F8, and 10 % rel ase was achieved over seven days
for both formulations. The low-MW ester end-cap ed PLGA itself improved the release profile ( F5)
compared with a blend of acid end-capped PLGAs (F10). The 24 h burst release decreased significantly
(****, p < 0.0001) from 53.2% for F10 to 33.2% for F5, and 100% of ketamine was released in two weeks.
Two- ay ANOVA followed by the Bonferroni tests. F, Formulation.
3.2.1. Reducing the Ketamine Payload Reduced the Burst Release of Ketamine
When the ketamine payload exceeded 60%, all the ketamine-loaded microparticles formulated
with various polymer compositions (high MW vs. low MW) performed similarly in vitro. The 24 h
burst release values were over 70% for all trials (e.g., formulations (F) 1–4 in Figure 1). Therefore,
the ketamine payload was reduced to 30%, which enabled a greater portion of the microparticle
composition to be polymer-controlled and resulted in a reduction of the burst release of ~40% (from
~70% down to ~30%) (Figures 1 and 2). A 14-day sustained release profile was achieved (Figure 2)
for F5 (30% ketamine +70% PLGA5050-1.5E) together with a significantly reduced 24 h burst release
(****, p < 0.0001) when compared with the corresponding parameters for F2 (60% ketamine + 40%
PLGA5050-1.5E) using the same polymer PLGA5050-1.5E (Figure 2).
For microparticles formed using the polymer PLGA5050-1.5E, a further reduction in the ketamine
loading from 30% to 10% enabled the polymer matrix to have better control over the release profile
(Figure 2). Sustained release was extended for more than 21 days for F6 (10% ketamine + 90%
PLGA5050-1.5E), and the 24 h burst release was reduced significantly (p < 0.0001) when loading was
reduced from ~30% to ~10% compared with F5 (30% ketamine + 70% PLGA5050-1.5E). The release
profile for microparticles loaded with 20% ketamine (F7, 20% ketamine + 80% PLGA5050-1.5E) did not
differ significantly when compared with 30% ketamine-loaded microparticles (F5) (p > 0.05) (Figure 2),
although the 24 h burst release was reduced from 27.7% to 17.5%.
3.2.2. Ester End-Capped Polymers Are Better at Controlling the Release of Ketamine Compared with
Acid End-Capped Polymers
The polymers used in this study were PLGAs and PLAs with varying molecular weights (MW)
and end-group functionalities. The physicochemical properties of the polymers used in this study are
summarized in Table 1. Particles formulated using acid end-capped polymers had a high burst release,
that is, ~55% release within the initial 24 h and >80% release within three days (Figure 3). Together,
our data show that for acid end-capped PLGAs, changing the MW/viscosity and possibly the particle
matrix had little influence on the rate of release. Our data show a maximum of one-week release in vitro
with acid end-capped PLGA polymers (Figure 3). Additionally, varying the ratios of the PLGA5050-1A
and the PLGA7525-4A polymers had little influence on the release profiles. High-MW acid end-capped
polymers did not perform significantly better than low-MW acid end-capped polymers. Incorporation
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of a low-MW ester end-capped polymer PLGA5050-1.5E (50%) into PLGA7525-4A (20%) reduced the
rate of ketamine release and extended the release over seven days (F8 in Figure 4). Ester end-capped
polymers enabled ketamine-loaded microparticles to be formed with release extended to 14 days and
more than 21 days (F5, F6, in Figure 2).
3.2.3. In Vitro Drug Release Kinetics
For the kinetic studies, the following plots were made: % drug release versus time (zero-order
kinetic model); % drug release versus square root of time (Higuchi model); log % drug release
versus log time (Korsmeyer–Peppas model). All plots are given in the supplementary materials
(Figures S1–S3), and the results are summarized in Table 3. Most data fit well to the Higuchi model
and the Korsmeyer–Peppas model (R2 > 0.9000). The PLGA5050-1.5E-based F6 of 10% DL showed the
best fit (R2 = 0.9481) of the observed data to the zero-order model.
Table 3. Fit parameters of the kinetic model for the release of ketamine-loaded
PLGA5050-1.5E-based microparticles.
Kinetic Model Zero Order Higuchi Korsmeyer–Peppas
Equation Mt = K0tMt/M∞ = K0t
Mt = kHt1/2
Mt/M∞ = kHt1/2
Mt/M∞ = kKP tn
log (Mt/M∞) = log KKP + n× log t
Mechanism Case II Transport Fickian Diffusion Depends on n Value, Shape and Material
Formulation Slope R2 Slope R2 Log KKP KKP n R2
Ketamine-loaded PLGA5050-1.5E-based microparticles with different theoretical DL (Figure 2)
F6 (10%) 0.0023 0.9481 0.4070 0.9140 −0.4457 0.640 0.4824 0.8330
F7 (20%) 0.0051 0.8735 0.7608 0.9274 −0.1998 0.819 0.5037 0.9028
F5 (30%) 0.0045 0.8807 0.6891 0.9726 0.4900 1.633 0.3396 0.9041
F2 (60%) 0.0068 0.5405 0.8525 0.7918 0.8657 2.377 0.2861 0.8824
Ketamine-loaded microparticles with different polymers at 30% theoretical loading
F10 0.0090 0.7758 1.0347 0.9521 0.1669 1.182 0.4737 0.9707
F11 0.0086 0.7848 0.9934 0.9591 0.3984 1.489 0.4085 0.9849
F12 0.0086 0.7728 0.9892 0.9526 0.3100 1.363 0.4322 0.9742
F14 0.0020 0.6643 0.4130 0.8559 0.8738 2.396 0.2355 0.9497
F15 0.0014 0.8026 0.3114 0.9331 0.7634 2.146 0.2271 0.9006
F17 0.0020 0.8292 0.4294 0.9251 0.8703 2.388 0.2344 0.9120
Reference [30] [31,32]
DL, drug loading; K0 is the zero-order release constant; KH is the Higuchi dissolution constant; Kkp is the Korsmeyer
release rate constant; Mt/M∞ is a fraction of drug released at time t; Mt is the amount of drug released in time t;
M∞ is the amount of drug released after time ∞; n is the diffusional exponent or drug release exponent.
3.3. Morphology and Particle Size
Visual inspection of the scanning electron micrograph images of F6 (the best performing
sustained-release profile herein) in Figure 5 show that the microparticles were random in shape
without significant aggregation and/or porosity and were in the size range of 20–45 µm. There was no
clear change in particle morphology after six months storage at 2–8 ◦C (Figure 5B).
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4. Discussion
In the present study, we demonstrate for the first time that the microencapsulation of ketamine
using supercritical CO2 technology resulted in microparticles that were solvent- and surfactant-free
once CO2 was converted from the liquid to the gaseous state and vented to the atmosphere [22].
Carbon dioxide is relatively inert, non-toxic, and environmentally friendly when compared with
organic solvents and emulsifying agents used in classical double-emulsion microparticle formulation
methods [16]. As CO2 has a relatively low critical point of 7.38 MPa at 31.1 ◦C, drug-loaded
microparticles can be processed under ambient conditions [33]. Our ketamine data herein highlight
the applicability of scCO2 for the incorporation of small bioactive molecules into a range of polymer
matrices to achieve the desired release profiles. Importantly, ketamine loading of these polymeric
microparticle formulations could be controlled in the range of 10–60%, with EE in the range of 60–100%.
For microparticles with ketamine loading in the range of 10–30%, the microencapsulated payloads
were 1.5–4.0-fold higher (Table 2) than those achieved in our previous work (6.8%) using a w/o/w
double emulsion method (Han et al., 2015). The particle sizes were mainly 20–45 µm (Figure 5), which
was within our target size range of 20–60 µm (Han et al., 2015), and in vitro ketamine release was
observed over a period of 0.5–4.0 weeks (Figures 2–4).
A greater proportion of polymer than encapsulated payload is required to achieve prolonged
release. Our findings show that for ketamine, microparticle loading up to a maximum of 30%
produced prolonged-release microparticles. Reducing the ketamine payload from 60% to 30% and
then to 10% progressively reduced the burst release effect. However, on the flip side, reducing
the encapsulated drug payload might adversely affect the requirement of achieving a therapeutic
response in vivo (60–100 µg per day), but this remains to be assessed. Our finding that the ketamine
release profile was prolonged by increasing the percentage of polymer in the formulation is aligned
with work by others [34] whereby the polymer/encapsulated drug ratio was an important factor in
controlling the rate of release. Herein, we found that to achieve prolonged release over 21 to 28 days,
the polymer-to-microencapsulated ketamine ratio should be 70:30 or 90:10.
Although higher drug loading led to more extensive burst release, the level of drug loading
had little effect on the release rate after 24 h, even when the drug loading was as high as 60%.
Drug release from PLGA microparticles is underpinned by three factors, namely, external diffusion,
internal mass transfer, and polymer degradation [35]. On the basis of our present results, the external
diffusion and internal mass transfer likely determine the extent of ketamine release during the first
24 h, and polymer degradation is the main factor controlling release thereafter. Our data extend
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the findings of Cai et al. [36] and Sah et al. [37] who showed that the concentration gradient does
not influence encapsulated drug release until the onset of polymer degradation. In previous work
by others using a double-emulsion method, a relatively high drug loading produced a particulate
dispersion characterized by increased microparticle porosity rather than the desired molecular
dispersion [36,38,39]. This underscores our present finding that higher ketamine loading led to a
greater burst release. Another explanation is that some ketamine may have precipitated on the surface
of the polymer rather than being incorporated into the polymer matrix [25], causing a relatively high
apparent burst drug release.
Our present data show that the use of this supercritical CO2 approach with the ester end-capped
PLGA5050-1.5E resulted in microparticles with superior burst and sustained-release properties
when compared with those produced using a range of PLGAs and PLAs either individually or
in various blends. This could be due to the low glass transition temperature of PLGA5050-1.5E
that enabled drug-loaded particles to be formed relatively quickly (Tg = 28.3 ◦C). Additionally,
when the temperature of the scCO2 process is above that of the polymer Tg, this allows higher CO2
sorption and swelling to enhance diffusion of the CO2/ketamine solution into the polymer matrix [40].
Microporosity of the PLGA5050-1.5E-based microparticles is likely to be the major factor aiding the
diffusion of ketamine out of the CriticalMix microparticles, causing burst release as the larger area
exposed for hydration facilitates rapid diffusion [41]. This is despite the fact that PLGA5050-1.5E has a
relatively low inherent viscosity, a property conducive to the formation of particles with smaller pores
or without pores. This topic has not been adequately addressed in published studies to date.
Our present data also show that hydrophobic ester end-capped PLGAs are superior at controlling
release compared with acid end-capped PLGAs, with the latter showing high burst ketamine release
at ~55%, with 100% release within one week (Figure 3) but without adversely affecting the drug
incorporation efficiency (Table 2). Our findings for ketamine are in contrast to work by others [36,42]
using a classical emulsion method to microencapsulate large molecules (dextran and bovine serum
albumin, respectively), whereby the hydrophilic acid end-capped PLGA RG503H (PLGA5050, MW
24–38 kDa, IV 0.32–0.44 dL/g, acid end-capped) led to a high drug loading and sustained release
(~4 weeks). For the more hydrophobic RG502 (PLGA5050, MW 7–17 kDa, IV 0.16–0.24 dL/g, ester
end-capped), these large molecules were trapped in the matrix and kept in the solid state because of
the delayed hydration process [36]. In the current study, it is likely that the delayed hydration process
of ester end-capped PLGAs [43] influenced the rate of polymer hydration in vitro and subsequently
facilitated the release of ketamine out of the microparticles. This is in agreement with the findings by
others that the encapsulation of weakly basic drugs into PLGA can accelerate the biodegradation of
PLGA [44,45]. Additionally, the acids may also produce local lowering of the pH [35] to accelerate
ketamine release. Therefore, to ensure that the release of the free base forms of small weakly basic
molecules, such as ketamine, can be controlled for a longer period, acid end-capped polymers should
be avoided.
For ketamine-release kinetics, the high correlation coefficients for the Higuchi and
Korsmeyer–Peppas models suggest a Fickian diffusion mechanism for most formulations [30–32].
The lowest burst release profile of F6 (10% DL, PLGA5050-1.5E based) fitted well to the zero-order
model but not well to the Korsmeyer–Peppas model (R2 = 0.8330, n = 0.4824), suggesting that Fickian
diffusion may play a critical role in the burst release.
Previous work by others has demonstrated that the drug release profile could be tailored by
altering the molar ratio of the different MW PLGA polymers used in the depot formulation [46]. It was
found that PLGA blends generally had intermediate properties when compared with pure polymer
formulations [46], suggesting that blends of low-, medium-, and high-MW polymers may form dense
and less porous microparticles, enabling a better control of sustained-release properties. However,
our data show that burst release was not improved as anticipated for these blended formulations.
An alternative approach is to include excipients which swell on contact with water, such as poloxamer
407 (Koliphor F407) [47,48], with the aim of filling the exposed microparticle pores and slow the rate of
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encapsulated payload diffusion. Thus, polymers/excipients, which become molten at physiological
temperature closing up the pores and thereby reducing the overall surface area exposed [49], should
be beneficial for extended-release formulations [50]. Hence, future work aimed at the investigation of
combinations of PLGA5050-1.5E with various swelling agents to reduce ketamine burst release may
be beneficial in further increasing ketamine loading without compromising the desired zero-order
sustained release profile.
5. Conclusions
The preparation of ketamine-encapsulated microparticles was successfully achieved using
supercritical fluid polymer encapsulation with EE in the range 60–100% in the absence of surfactants
and potentially toxic organic solvents. A sustained-release profile extending for≥21 days was achieved
using ester end-capped PLGA5050-1.5E at drug loading of 10% in vitro. It is clear from our findings that
payload solubility in scCO2 as well as CO2 sorption and swelling of the polymer vary with temperature,
pressure, contact time, stirring rate of the scCO2/polymer/drug solution, as well as depressurization
conditions including CO2 venting rate and venting temperature. By systematically varying these
parameters and by selecting PLGAs with different physicochemical properties (end groups, viscosity,
etc.), small molecule-loaded microparticles with the desired release rate can be produced using
supercritical fluid polymer encapsulation instead of organic solvents and emulsifiers that are difficult
and costly to remove.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/10/4/264/s1,
Figure S1: Drug release kinetics plots of F2, F5, F6 and F7. Figure S2: Drug release kinetics plots of F10, F11 and
F12. Figure S3: Drug release kinetics plots of F14, F15 and F17. Figure S4: DSC curves of PLGA5050-1.5E before
and after loading with ketamine. The curves displayed above are the 2nd heating. Heating rate is 10 ◦C/min from
0 to 300 ◦C. Figure S5: FTIR spectra of PLGA5050-1.5E before and after loading with ketamine.
Author Contributions: Conceptualization, M.T.S., A.K.W., F.Y.H and S.M.H.; methodology, A.K.H., S.M.H. and
A.S.-A.; formal analysis, F.Y.H.; investigation, M.T.S., A.K.W., F.Y.H., A.S.-A. and S.M.H.; resources, S.M.H., A.N.,
A.K.W. and M.T.S.; data curation, A.S.-A., A.N., C.Z. and F.Y.H.; writing—original draft preparation, F.Y.H.;
writing—review and editing, F.Y.H., M.T.S., S.M.H., A.N. and A.K.W.; project administration, F.Y.H., M.T.S. and
A.K.W.; funding acquisition, M.T.S. and A.K.W.
Funding: This research was funded by a National Health and Medical Research Council (NHMRC) Grant
[APP1107723]. Financial support from the Australian Research Council (LE0775684, LE110100028, LE110100033,
LE140100087, LE160100168) is also acknowledged.
Acknowledgments: The authors acknowledge the Queensland Government Smart State Research Facilities
Programme for supporting CIPDD research infrastructure. CIPDD is also supported by Therapeutic Innovation
Australia (TIA). TIA is supported by the Australian Government through the National Collaborative Research
Infrastructure Strategy (NCRIS) program. The particles were produced at Critical Pharmaceuticals Limited,
Nottingham, United Kingdom. The authors also acknowledge the use of the equipment managed by the Australian
National Fabrication Facility (ANFF-Q) at The University of Queensland. We thank Tushar Kumeria from the
School of Pharmacy, University of Queensland, for his useful inputs on release kinetics and models.
Conflicts of Interest: The authors have no conflicts of interest to declare in association with this work. The funders
had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the
manuscript, or in the decision to publish the results.
References
1. Paice, J.A.; Betty, F. The Management of Cancer Pain. CA Cancer J. Clin. 2011, 61, 157–182. [CrossRef]
[PubMed]
2. Aboawja, M. Patterns of Cancer Diagnoses Referred to Palliative Medicine in a Tertiaryhospital in
Dammam-Saudi Arabia. J. Nurs. Healthcare 2017, 2, 1–4.
3. Nersesyan, H.; Slavin, K.V. Current Aproach to Cancer Pain Management: Availability and Implications of
Different Treatment Options. Ther. Clin. Risk Manag. 2007, 3, 381–400. [PubMed]
4. Stearns, L.; Boortz-Marx, R.; Du Pen, S.; Friehs, G.; Gordon, M.; Halyard, M.; Herbst, L.; Kiser, J. Intrathecal
Drug Delivery for the Management of Cancer Pain: A Multidisciplinary Consensus of Best Clinical Practices.
J. Support. Oncol. 2005, 3, 399–408.
Pharmaceutics 2018, 10, 264 12 of 14
5. Bhatia, G.; Lau, M.E.; Koury, K.M.; Gulur, P. Intrathecal Drug Delivery (ITDD) Systems for Cancer Pain.
F1000Res 2013, 2, 96. [CrossRef] [PubMed]
6. Yang, C.Y.; Wong, C.S.; Chang, J.Y.; Ho, S.T. Intrathecal Ketamine Reduces Morphine Requirements in
Patients with Terminal Cancer Pain. Can. J. Anaesth. 1996, 43, 379–383. [CrossRef] [PubMed]
7. Chang, A.K.; Bijur, P.E.; Meyer, R.H.; Kenny, M.K.; Solorzano, C.; Gallagher, E.J. Safety and Efficacy of
Hydromorphone as an Analgesic Alternative to Morphine in Acute Pain: A Randomized Clinical Trial. Ann.
Emerg. Med. 2006, 48, 164–172. [CrossRef]
8. Jonkman, K.; van de Donk, T.; Dahan, A. Ketamine for Cancer Pain: What Is the Evidence? Curr. Opin.
Support Palliat Care 2017, 11, 88–92. [CrossRef]
9. Jonkman, K.; Dahan, A.; van de Donk, T.; Aarts, L.; Niesters, M.; van Velzen, M. Ketamine for Pain. F1000Res
2017, 6. [CrossRef]
10. Miyamoto, H.; Saito, Y.; Kirihara, Y.; Hara, K.; Sakura, S.; Kosaka, Y. Spinal Coadministration of Ketamine
Reduces the Development of Tolerance to Visceral as Well as Somatic Antinociception During Spinal
Morphine Infusion. Anesth. Analg. 2000, 90, 136–141. [CrossRef]
11. Markman, J.D.; Philip, A. Interventional Approaches to Pain Management. Med. Clin. North Am. 2007, 91, 271.
[CrossRef] [PubMed]
12. Han, F.Y.; Thurecht, K.J.; Lam, A.L.; Whittaker, A.K.; Smith, M.T. Novel Polymeric Bioerodable Microparticles
for Prolonged-Release Intrathecal Delivery of Analgesic Agents for Relief of Intractable Cancer-Related Pain.
J. Pharm. Sci. 2015, 104, 2334–2344. [CrossRef]
13. Danhier, F.; Ansorena, E.; Silva, J.M.; Coco, R.; le Breton, A.; Préat, V. Plga-Based Nanoparticles: An Overview
of Biomedical Applications. J. Control. Release 2012, 161, 505–522. [CrossRef] [PubMed]
14. Han, F.Y.; Thurecht, K.J.; Whittaker, A.K.; Smith, M.T. Bioerodable Plga-Based Microparticles for Producing
Sustained-Release Drug Formulations and Strategies for Improving Drug Loading. Front. Pharmacol.
2016, 7, 185. [CrossRef] [PubMed]
15. Makadia, H.K.; Siegel, S.J. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery
Carrier. Polymers 2011, 3, 1377–1397. [CrossRef] [PubMed]
16. Falk, R.F.; Randolph, T.W. Process Variable Implications for Residual Solvent Removal and Polymer
Morphology in the Formation of Gentamycin-Loaded Poly(L-Lactide) Microparticles. Pharm. Res.
1998, 15, 1233–1237. [CrossRef] [PubMed]
17. Garcia-Gonzalez, C.A.; Concheiro, A.; Alvarez-Lorenzo, C. Processing of Materials for Regenerative Medicine
Using Supercritical Fluid Technology. Bioconj. Chem. 2015, 26, 1159–1171. [CrossRef]
18. Kelly, C.A.; Naylor, A.; Illum, L.; Shakesheff, K.M.; Howdle, S.M. Supercritical CO2: A Clean and Low
Temperature Approach to Blending Pdlla and Peg. Adv. Funct. Mater. 2012, 22, 1684–1691. [CrossRef]
19. Tabernero, A.; del Valle, E.M.M.; Galan, M.A. Supercritical Fluids for Pharmaceutical Particle Engineering:
Methods, Basic Fundamentals and Modelling. Chem. Eng. Process. 2012, 60, 9–25. [CrossRef]
20. Del Valle, E.M.M.; Galan, M.A. Supercritical Fluid Technique for Particle Engineering: Drug Delivery
Applications. Rev. Chem. Eng. 2005, 21, 33–69.
21. Howdle, S.M.; Watson, M.S.; Whitaker, M.J.; Popov, V.K.; Davies, M.C.; Mandel, F.S.; Wang, J.D.;
Shakesheff, K.M. Supercritical Fluid Mixing: Preparation of Thermally Sensitive Polymer Composites
Containing Bioactive Materials. Chem. Commun. 2001, 1, 109–110. [CrossRef]
22. Nuchuchua, O.; Nejadnik, M.R.; Goulooze, S.C.; Lješkovic´, N.J.; Every, H.A.; Jiskoot, W. Characterization
of Drug Delivery Particles Produced by Supercritical Carbon Dioxide Technologies. J. Supercrit. Fluids
2017, 128, 244–262. [CrossRef]
23. Türk, M.; Bolten, D. Polymorphic Properties of Micronized Mefenamic Acid, Nabumetone, Paracetamol
and Tolbutamide Produced by Rapid Expansion of Supercritical Solutions (RESS). J. Supercrit. Fluids
2016, 116, 239–250. [CrossRef]
24. Kiran, E. Supercritical Fluids and Polymers—The Year in Review-2014. J. Supercrit. Fluids 2016, 110, 126–153.
[CrossRef]
25. Champeau, M.; Thomassin, J.M.; Tassaing, T.; Jérôme, C. Drug Loading of Polymer Implants by Supercritical
CO2 Assisted Impregnation: A Review. J. Control. Release 2015, 209, 248–259. [CrossRef] [PubMed]
26. Woods, H.M.; Silva, M.M.C.G.; Nouvel, C.; Shakesheff, K.M.; Howdle, S.M. Materials Processing in
Supercritical Carbon Dioxide: Surfactants, Polymers and Biomaterials. J. Mater. Chem. 2004, 14, 1663–1678.
[CrossRef]
Pharmaceutics 2018, 10, 264 13 of 14
27. Jordan, F.; Naylor, A.; Kelly, C.A.; Howdle, S.M.; Lewis, A.; Illum, L. Sustained Release Hgh Microsphere
Formulation Produced by a Novel Supercritical Fluid Technology: In Vivo Studies. J. Control. Release
2010, 141, 153–160. [CrossRef] [PubMed]
28. Baxendale, A.; van Hooff, P.; Durrant, L.G.; Spendlove, I.; Howdle, S.M.; Woods, H.M.; Whitaker, M.J.;
Davies, O.R.; Naylor, A.; Lewis, A.L.; et al. Single Shot Tetanus Vaccine Manufactured by a Supercritical
Fluid Encapsulation Technology. Int. J. Pharm. 2011, 413, 147–154. [CrossRef]
29. Whitaker, M.J.; Hao, J.Y.; Davies, O.R.; Serhatkulu, G.; Stolnik-Trenkic, S.; Howdle, S.M.; Shakesheff, K.M.
The Production of Protein-Loaded Microparticles by Supercritical Fluid Enhanced Mixing and Spraying.
J. Control. Release 2005, 101, 85–92. [CrossRef]
30. Dash, S.; Murthy, P.N.; Nath, L.; Chowdhury, P. Kinetic Modeling on Drug Release from Controlled Drug
Delivery Systems. Acta Poloniae Pharm. 2010, 67, 217–223.
31. Korsmeyer, R.W.; Gurny, R.; Doelker, E.; Buri, P.; Peppas, N.A. Mechanisms of Solute Release from Porous
Hydrophilic Polymers. Int. J. Pharm. 1983, 15, 25–35. [CrossRef]
32. Ritger, P.L.; Nikolaos, A.P. A Simple Equation for Description of Solute Release II. Fickian and Anomalous
Release from Swellable Devices. J. Control. Release 1987, 5, 37–42. [CrossRef]
33. Ginty, P.J.; Whitaker, M.J.; Shakesheff, K.M.; Howdle, S.M. Drug Delivery Goes Supercritical. Mater. Today
2005, 8, 42–48. [CrossRef]
34. Kilicarslan, M.; Baykara, T. The Effect of the Drug/Polymer Ratio on the Properties of the Verapamil HCl
Loaded Microspheres. Int. J. Pharm. 2003, 252, 99–109. [CrossRef]
35. Siepmann, J.; Elkharraz, K.; Siepmann, F.; Klose, D. How Autocatalysis Accelerates Drug Release from
PLGA-Based Microparticles: A Quantitative Treatment. Biomacromolecules 2005, 6, 2312–2319. [CrossRef]
[PubMed]
36. Cai, C.; Mao, S.; Germershaus, O.; Schaper, A.; Rytting, E.; Chen, D.; Kissel, T. Influence of Morphology and
Drug Distribution on the Release Process of Fitc-Dextran-Loaded Microspheres Prepared with Different
Types of Plga. J. Microencapsul. 2009, 26, 334–345. [CrossRef] [PubMed]
37. Sah, H.K.; Toddywala, R.; Chien, Y.W. The Influence of Biodegradable Microcapsule Formulations on the
Controlled-Release of a Protein. J. Control. Release 1994, 30, 201–211. [CrossRef]
38. Rivera, P.A.; Martinez-Oharriz, M.C.; Rubio, M.; Irache, J.M.; Espuelas, S. Fluconazole Encapsulation in
PLGA Microspheres by Spray-Drying. J. Microencapsul. 2004, 21, 203–211. [CrossRef]
39. Le Corre, P.; Rytting, J.H.; Gajan, V.; Chevanne, F.; le Verge, R. In Vitro Controlled Release Kinetics of
Local Anaesthetics from Poly(D,L-Lactide) and Poly(Lactide-co-Glycolide) Microspheres. J. Microencapsul.
1997, 14, 243–255. [CrossRef]
40. Guney, O.; Akgerman, A. Synthesis of Controlled-Release Products in Supercritical Medium. Aiche J. 2002, 48,
856–866. [CrossRef]
41. Buzea, C.; Pacheco, I.I.; Robbie, K. Nanomaterials and Nanoparticles: Sources and Toxicity. Biointerphases
2007, 2, MR17–MR71. [CrossRef] [PubMed]
42. Hora, M.S.; Rana, R.K.; Nunberg, J.H.; Tice, T.R.; Gilley, R.M.; Hudson, M.E. Release of Human
Serum-Albumin from Poly(Lactide-co-Glycolide) Microspheres. Pharm. Res. 1990, 7, 1190–1194. [CrossRef]
43. Yeo, Y.; Park, K. Control of Encapsulation Efficiency and Initial Burst in Polymeric Microparticle Systems.
Arch Pharm. Res. 2004, 27, 1–12. [CrossRef] [PubMed]
44. Cha, Y.; Pitt, C.G. The Acceleration of Degradation-Controlled Drug Delivery from Polyester Microspheres.
J. Control. Release 1989, 8, 259–265. [CrossRef]
45. D’Souza, S.; Faraj, J.A.; Dorati, R.; DeLuca, P.P. Enhanced Degradation of Lactide-co-Glycolide Polymer with
Basic Nucleophilic Drugs. Adv. Pharm. 2015, 10. [CrossRef]
46. Solorio, L.; Olear, A.M.; Hamilton, J.I.; Patel, R.B.; Beiswenger, A.C.; Wallace, J.E.; Zhou, H.Y.; Exner, A.A.
Noninvasive Characterization of the Effect of Varying PLGA Molecular Weight Blends on in Situ Forming
Implant Behavior Using Ultrasound Imaging. Theranostics 2012, 2, 1064–1077. [CrossRef] [PubMed]
47. Fakhari, A.; Corcoran, M.; Schwarz, A. Thermogelling Properties of Purified Poloxamer 407. Heliyon
2017, 3, e00390. [CrossRef] [PubMed]
48. Csaba, N.; Caamano, P.; Sanchez, A.; Dominguez, F.; Alonso, M.J. PLGA:Poloxamer and PLGA:Poloxamine
Blend Nanoparticles: New Carriers for Gene Delivery. Biomacromolecules 2005, 6, 271–278. [CrossRef]
Pharmaceutics 2018, 10, 264 14 of 14
49. Kang, J.C.; Schwendeman, S.P. Pore Closing and Opening in Biodegradable Polymers and Their Effect on the
Controlled Release of Proteins. Mol. Pharm. 2007, 4, 104–118. [CrossRef]
50. Al-Tahami, K.; Singh, J. Smart Polymer Based Delivery Systems for Peptides and Proteins. Recent Patents
Drug Deliv. Formul. 2007, 1, 65–71. [CrossRef]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
